Cardiol Therapeutics Inc. (CRDL) Stock Score, Valuation & Financial Research

Cardiol Therapeutics Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CRDL

Cardiol Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.31. These figures are a research snapshot, not a buy or sell recommendation.

What Cardiol Therapeutics Inc. does

Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Cardiol Therapeutics is a clinical-stage life sciences company that does not currently generate revenue from product sales. Its business model focuses on the research and development of anti-inflammatory and anti-fibrotic therapies for heart disease, funded through equity offerings and capital raises to support ongoing clinical trials.

Products and services

  • The company is developing CardiolRx, a pharmaceutically manufactured cannabidiol formulation for recurrent pericarditis, and CRD-38, a novel drug formulation for heart failure.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages various third-party contract research organizations to manage and conduct its multi-center clinical trials. Source

Business strengths to evaluate

  • Clinical-stage pipeline focused on high-unmet-need heart disease therapies Source

Business risks and research considerations

  • History of operating losses and dependence on future capital raises to fund clinical development Source
  • Uncertainty and risks associated with clinical trial outcomes and regulatory approval processes Source

Sources: Company research source · Contract Research Organizations (CROs) · History of operating losses and dependence on future capital raises to fund clinical development

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CRDL financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.31
Market capitalization:
151.01M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -25.8M
Free cash flow:
USD -16.8M
Cash:
USD 18.36M
Total debt:
USD 75.31K
EPS:
USD -0.26

What stands out

  • Free cash flow is USD -16.8M, negative for the stored period.
  • The balance sheet shows USD 18.36M of cash versus USD 75.31K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 18.28M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CRDL

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CRDL fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CRDL likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CRDL to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CRDL's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CRDL

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.